NTRK GENE FUSIONS | Clinical

FDA Clears Phase 1/2 Study of ABT-101 in Non–Small Cell Lung Cancer

September 14, 2022

The FDA has granted approval for an investigational new drug protocol amendment for ABT-101, a mutant selective tyrosine kinase inhibitor which has shown superior selectivity against HER2 exon 20 mutations in NSCLC in preclinical studies.